Literature DB >> 21239816

Clinical use of intravenous iron: administration, efficacy, and safety.

Michael Auerbach1, Harold Ballard.   

Abstract

This section reviews the history, pharmacology, administration, efficacy, and toxicity of intravenous iron. Intravenous iron offers advantages over oral iron for the treatment of iron deficiency anemia across a wide range of disease states associated with absolute and functional iron deficiency. However, there remain concerns about the acute safety profiles of the available preparations and the potential for long-term toxicity with their repeated administration. Seven intravenous iron formulations are available. Confusion concerning the relative toxicities of the different formulations abounds. The similarities and differences are discussed. Iron repletion has been associated with adverse outcomes in infections. The relationship, if any, between intravenous iron administration and infections is reviewed. The potential advantages of total dose infusion (TDI), complete repletion in a single setting, are highlighted. A new paradigm for iron replacement therapy in iron deficiency anemia is presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21239816     DOI: 10.1182/asheducation-2010.1.338

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  75 in total

1.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

2.  Iron-deficiency anaemia in the Emergency Room: a new opportunity for the use of intravenous iron.

Authors:  Dan Morhaim; Michael Auerbach
Journal:  Blood Transfus       Date:  2015-11-19       Impact factor: 3.443

3.  Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer® ) versus ferric carboxy-maltose (Ferinject® ). A single center, cohort study.

Authors:  Midas B Mulder; Hester L van den Hoek; Erwin Birnie; Antonie J P van Tilburg; Elsbeth M Westerman
Journal:  Br J Clin Pharmacol       Date:  2018-12-11       Impact factor: 4.335

Review 4.  [Patient Blood Management : three pillar strategy to improve outcome through avoidance of allogeneic blood products].

Authors:  H Gombotz; A Hofmann
Journal:  Anaesthesist       Date:  2013-07       Impact factor: 1.041

Review 5.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 6.  Management of Anemia in Patients with Inflammatory Bowel Disease (IBD).

Authors:  Dhruvan Patel; Chinmay Trivedi; Nabeel Khan
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

7.  IBD: Intravenous iron in IBD--what's the best preparation?

Authors:  Fernando Gomollón; Javier P Gisbert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-26       Impact factor: 46.802

Review 8.  Perioperative anemia management in colorectal cancer patients: a pragmatic approach.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Elisa Martín-Montañez; Michael Auerbach
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

9.  Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing.

Authors:  Alina Daba; Konstantinos Gkouvatsos; Giada Sebastiani; Kostas Pantopoulos
Journal:  J Mol Med (Berl)       Date:  2012-07-31       Impact factor: 4.599

Review 10.  Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people?

Authors:  Hui Sian Tay; Roy L Soiza
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.